Explain this page
Arphra AIPlain-English read on Merck & Co., Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$137.71
+14.01% vs spot
Recommendation
Buy
19 of 20 methods
Method spread
6bull13bear
±5% threshold
Analyst PT consensus: $129.31 (+7.05%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.52% | +2.04% | +7.90% | +5.19% | +22.43% | +15.99% | +57.29% | +7.94% | +67.71% | +123.98% | +30779.94% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$23.26M
10 txns
Net flow
−$23.26M
Aftermarket
LiveLast trade
$122.09
145 sh
Bid
$115.24
1 sh
Ask
$128.24
100 sh
Spread
$13.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $16.29B | -$4.24B | $-1.72 |
| Q4 Dec 2025 | $16.32B | $2.96B | $1.19 |
| Q3 Sep 2025 | $17.18B | $5.79B | $2.32 |
| Q2 Jun 2025 | $15.8B | $4.43B | $1.76 |
| Q1 Mar 2025 | $15.62B | $5.08B | $2.01 |
| Q4 Dec 2024 | $15.62B | $3.74B | $1.48 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$129.31
+7.05% upside
Low
$100.00
Median
$133.00
High
$150.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promiseseekingalpha.com·Jun 05, 2026
- Merck (MRK) Recently Broke Out Above the 20-Day Moving Averagezacks.com·Jun 05, 2026
- Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investorszacks.com·Jun 05, 2026
- Merck: Navigating the Patent Cliff and Future Growth Prospectsfool.com·Jun 04, 2026
- Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 04, 2026
- Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?zacks.com·May 13, 2026
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026businesswire.com·May 12, 2026
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026businesswire.com·May 12, 2026
Peers
Total assets
$136.87B
Total debt
$50.53B
Cash & equiv
$14.57B
Operating CF
$16.47B
Free cash flow
$12.36B
Buybacks
-$5.08B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Guindo Chirfi officer: Chief Marketing Officer | Sell | 10,000 | $1.21M | Feb 12, 2026 |
Li Dean Y officer: Executive VP & President, MRL | Sell | 10,235 | $1.2M | Feb 10, 2026 |
Zachary Jennifer officer: EVP, General Counsel | Sell | 38,835 | $4.63M | Feb 09, 2026 |
Guindo Chirfi officer: Chief Marketing Officer | Sell | 10,000 | $1.18M | Feb 09, 2026 |
Oosthuizen Johannes Jacobus officer: President, U.S. Market | Sell | 15,000 | $1.83M | Feb 06, 2026 |
DeLuca Richard R. officer: EVP&Pres, Merck Animal Heallth | Sell | 37,685 | $4.56M | Feb 06, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $64.93B | $23.49B | $18.25B | $7.28 | +28.12% |
| FY 2024 | $64.17B | $20.22B | $17.12B | $6.74 | +26.68% |
| FY 2023 | $60.12B | $2.95B | $365M | $0.14 | +0.61% |
| FY 2022 | $59.28B | $18.28B | $14.52B | $5.71 | +24.49% |
| FY 2021 | $48.7B | $13.2B | $13.05B | $5.14 | +26.79% |